Medtronic (Minneapolis) received a crucial component in bringing its CoreValve system for transcatheter aortic valve implantation (TAVI) to the U.S. The med-tech giant reported last week that the FDA has given conditional approval for its investigational device exemption application and pivotal clinical trial protocol to evaluate the device.(Medical Device Daily) Read More
